Tandem Diabetes Care Forecast and Stock Analysis
Technical TNDM stock analysis for February 15, 2019.
Tandem Diabetes Care gained 4.50% in the last trading day, rising from $49.28 to $51.50 , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. The price has risen in 7 of the last 10 days and is up by 21.2% over the past 2 weeks. Volume fell in the last day by -0.50 million shares, and in total, 2.20 million shares bought and sold for approximately $113.43 million. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.
Close price at the end of the last trading day (Friday, 15th Feb 2019) of the TNDM stock was $51.50. This is 4.5% more than the trading day before Thursday, 14th Feb 2019.
During day the stock fluctuated 3.91% from a day low at $50.07 to a day high of $52.03.
30 day high of the TNDM stock price was $52.03 and low was $40.46.
90 day high was $52.03 and low was $26.40.
52 week high for the Tandem Diabetes Care - $52.55 and low - $2.39.
Tandem Diabetes Care has broken the very wide and strong rising the short-term trend up and an even stronger rising rate is indicated. For any reaction back there will now be support on the roof on the current trend broken at $50.79, a level that may pose a second chance to hit a runner. According to fan-theory $61.82 will be the next possible trend-top level and thereby pose a resistance level which may not be broken at the first attempt.
Only positive signals in the chart today. Tandem Diabetes Care holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at $45.97 and $41.90. A break down below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Thursday February 07, 2019, which indicates further gains until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and may be an early warning. The stock should be watched closely.
Relative Strength Index (RSI)
The stock holds a RSI14 at 77 and is currently being overbought on RSI. This does not have to be a sales signal as many stocks may go both long and hard while being overbought on the RSI. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness.
Support & Resistance
Tandem Diabetes Care finds support from accumulated volume at $49.28.
This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.96 between high and low, or 3.91%. For the last week, the stock has had a daily average volatility of 7.01%.
The stock is extremely overbought on RSI14 (77). Normally this will pose a good selling opportunity, but since the stock has broken the trend up the chance for a major correction due to high RSI is very small as the stock will find support at the trend broken.
Our recommended stoploss: $49.71 (-3.47%) (This stock has medium daily movements and this gives medium risk. The RSI14 is 77 and this increases the risk substantially. There is a buy signal from pivot bottom found 6 days ago.)
Very Low Low Medium High Very High
Evaluation: Strong Buy Candidate
Tandem Diabetes Care holds several positive signals and has broken the strong rising trend up. As the stock is also in great technical shape, we therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.